Teva Strikes Two Major Deals For Eculizumab And Aflibercept Biosimilars

Samsung And Formycon Supply US Soliris And European Eylea Rivals

Teva has announced two major biosimilars deals in quick succession, partnering with Samsung Bioepis on its US Epysqli eculizumab rival to Soliris and Formycon on its European Ahzantive aflibercept challenger to Eylea.

Teva has struck a pair of biosimilars deals in the US and Europe (Shutterstock)

Teva has bolstered its biosimilars business with a pair of alliances that will give the Israeli off-patent giant rights to Samsung Bioepis’ Soliris (eculizumab) rival in the US and Formycon’s version of Eylea (aflibercept) in Europe.

More from Deals

More from Products